SCHEMBL280366

SCHEMBL280366

Cc1ccc(C(=O)CN(c2ccncc2)c2ccncc2)s1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.44
NPC1 O15118 6/20 0.44
DAO P14920 1/20 0.43
POLB P06746 3/20 0.40
ALDH1A1 P00352 3/20 0.40
CASP3 P42574 2/20 0.40
SENP8 Q96LD8 2/20 0.40
SENP7 Q9BQF6 2/20 0.40
SENP6 Q9GZR1 2/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
NAMPT P43490 1/20 0.37
MEN1 O00255 1/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279931 0.87 RAB9A (0.43) RAB9ANPC1DAOPOLBALDH1A1
SCHEMBL280054 0.84 RAB9A (0.41) RAB9ANPC1DAOPOLBALDH1A1
SCHEMBL279743 0.78 NPC1 (0.41) RAB9ANPC1DAOPOLBALDH1A1
SCHEMBL279750 0.76 USP2 (0.43) RAB9ANPC1DAOPOLBALDH1A1
SCHEMBL280207 0.76 NPC1 (0.37) RAB9ANPC1DAOPOLBALDH1A1
SCHEMBL280361 0.73 RAB9A (0.47) RAB9ANPC1DAOPOLBALDH1A1
SCHEMBL13060968 0.73 RAB9A (0.50) RAB9ANPC1DAOPOLBALDH1A1
SCHEMBL280370 0.73 RAB9A (0.38) RAB9ANPC1DAOPOLBALDH1A1
SCHEMBL279741 0.72 HSD11B1 (0.49) RAB9ANPC1DAOPOLBALDH1A1
SCHEMBL280130 0.72 NPC1 (0.44) RAB9ANPC1DAOPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL RAB9A 2458/4885NPC1 3107/4885DAO 1673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.